Hannah Dellabella

Researchers evaluated levels of serum anti-carbamylated protein antibodies and assessed their clinical value in systemic lupus erythematosus.

Researchers aimed to characterize prevalence of Sjögren syndrome among children with recurrent parotitis.

Investigators found data that showed that the documentation of a treat-to-target approach in rheumatoid arthritis was improved by a learning collaborative intervention with participation by rheumatologists and their patients.

This study was the first to evaluate both the prevalence of osteopenia and osteoporosis in a large cohort of patients with bronchiectasis and its relationship with other variables, including clinical, body composition and bone turnover, and inflammation markers.

Researchers investigated the relationship between smoking and imaging outcomes, including sacroiliac joints, spine, and MRI radiographs in patients with axial spondyloarthritis.

Researchers aimed to develop a stratification method to evaluate symptom prevalence and distinct treatment responses in patients with Sjogren syndrome.

A recent study indicated that among participants with rheumatoid arthritis, all autoantibodies followed a similar trajectory, with an early initial elevation, a period of stability, and an immediate increase pre-RA diagnosis.

Researchers evaluated the outcomes of patients with immune checkpoint inhibitor-induced inflammatory arthritis and assessed the risk factors for long-term disease requiring immunomodulatory treatment.

The study aimed to describe clinical characteristics, risk factors, histopathologic and immunologic features of systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD).

Using a Canadian registry of patients with rheumatoid arthritis, researchers found data that showed therapy with abatacept was consistent and remained so for a longer duration.

Osteopenia was found in more than 25% of both men and women, suggesting that more osteoporosis screening and prevention programs are needed in middle-age individuals.

Researchers found that testing adalimumab serum concentrations in the last serum sample from patients with rheumatoid arthritis from the Amsterdam Rheumatology and Immunology Center using enzyme-linked immunosorbent assays showed that patients with ≧5.0 μg/mL adalimumab had a lower response rate when switched to etanercept compared with patients who were biologic-naïve. However, researchers believe that a larger study population is required for more detailed results.

For patients with rheumatoid arthritis (RA), using conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) concomitantly with biologic DMARDs (bDMARDs) is associated with a significantly reduced risk for bDMARD discontinuation because of adverse events (AEs), according to results published in the Journal of Rheumatology. The study included participants from the Ontario Best Practices Research Initiative (OBRI) who…

Researchers found that in patients with a first-degree relative with rheumatoid arthritis, the antibodies to citrullinated protein/peptide antigens indicate an association with aging for those aged 50 or older and rheumatoid arthritis pathogenesis.

Researchers found data which showed that approximately 27% of patients (n=105) with atlanto-axial pannus located on their spines had rheumatoid arthritis, but the investigators believe it is unlikely that their older cohort of patients with incidental atlanto-axial pannus on the cervical spine has undiagnosed rheumatoid arthritis.

The researchers found data that the approximate median time to complete the Routine Assessment of Patient Index Data 3 was 116 seconds vs 35 seconds for the Patient-Reported Outcomes Measurement Information System (PROMIS) and showed comparable results, so they believe that the PROMIS is a way for patients to save time and clinicians to collect other valuable information.

Participants with early rheumatoid arthritis in the Swedish Pharmacotherapy clinical trial who were treated with methotrexate therapy for 3 months were found to have baseline level biomarkers of low C-reactive protein and leptin with high tumor necrosis factor receptor 1 and vascular cell adhesion molecule 1 that were associated with low disease activity.

Researchers noted improved outcome measures for the combined use of HCQ and other csDMARDs in patients with rheumatoid arthritis with a history of insufficient response to treatment.

Denosumab is a potentially useful treatment option for patients with rheumatoid arthritis with rheumatoid factor and anti-citrullinated protein antibodies who are receiving methotrexate.

Researchers analyzed the effect of a risk-stratified DMARD-tapering algorithm based on MBDA score and ACPA on direct treatment costs for patients with RA in sustained remission.

Intensive treatment with combination DMARDs, biologics, or JAK inhibitors increased the likelihood of achieving remission in patients with early and established RA.

Investigators identified several metabolites associated with achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies.

For patients with rheumatoid arthritis treated with biologic DMARDs, disease stage, health assessment questionnaire score at 18 months, and Larsen grade of joints at the start of treatment may be predictive of radiographic progression of damage to large joints after 3 to 4 years of treatment.

Overall, the PROMIS Physical Function Short Form has good measurement properties and is both practical and acceptable for implementation in routine clinical practice.

Baseline disease characteristics and early disease activity in patients with rheumatoid arthritis can predict response to methotrexate treatment and radiographic progression at 6 months.

Both neuromuscular electrical stimulation and high-intensity volitional resistance training can effectively improve muscle structure and function in rheumatoid arthritis.

A study sought to address whether adding baseline ultrasonography of the hands, wrists, and feet to baseline characteristics improved the prediction of failure to achieve remission in Disease Activity Score assessing 28 joints at 12 months.